Overview Dividends

(LUNG) Pulmonx - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US7458481014

Valve, Catheter, Console, Cloud, Analysis

LUNG EPS (Earnings per Share)

EPS Growth (3Y CAGR): 14.90%
EPS Trend (3Y Correlation): 67.1%

LUNG Revenue

Revenue Growth (3Y CAGR): 12.84%
Revenue Trend (3Y Correlation): 92.2%

Risk via 10d forecast
Volatility	99.1%
Value at Risk 5%th	147%
Relative Tail Risk	-10.04%

Reward TTM
Sharpe Ratio	-1.08
Alpha	-90.54

Character TTM
Hurst Exponent	0.537
Beta	0.774
Beta Downside	0.665

Drawdowns 3y
Max DD	89.83%
Mean DD	40.37%
Median DD	43.24%

Description: LUNG Pulmonx November 11, 2025

Pulmonx Corp. (NASDAQ:LUNG) is a commercial-stage medical-technology firm that delivers minimally invasive therapies for severe emphysema, a subset of chronic obstructive pulmonary disease (COPD). Its flagship Zephyr Endobronchial Valve is complemented by the Chartis Pulmonary Assessment System- a balloon catheter with flow and pressure sensors that evaluates collateral ventilation- and the LungTraX Platform, a cloud-based CT-analysis service offering tools such as LungTraX Connect, LungTraX Detect, and StratX Lung reports to streamline patient work-up and target-lobe selection. The company operates across the United States, Europe, the Middle East, Africa, and the Asia-Pacific.

Key recent metrics include Q4 2024 revenue of approximately $45 million, a cash balance of $120 million giving it roughly 18 months of runway at current burn rates, and a 23 % year-over-year increase in Zephyr valve implantations driven by expanding reimbursement coverage in the U.S. and Europe. The global COPD market is projected to grow at a 4.5 % CAGR through 2030, buoyed by an aging population and rising smoking-related disease prevalence, which underpins Pulmonx’s long-term demand outlook.

For a deeper, data-driven assessment of LUNG’s valuation and risk profile, you may find ValueRay’s analytical dashboard a useful next step.

LUNG Stock Overview

Market Cap in USD	65m
Sub-Industry	Health Care Equipment
IPO / Inception	2020-10-01
Return 12m vs S&P 500	-79.0%
Analyst Rating	4.29 of 5

LUNG Dividends

Currently no dividends paid

LUNG Growth Ratios

CAGR 3y	-37.63%
CAGR/Max DD Calmar Ratio	-0.42
CAGR/Mean DD Pain Ratio	-0.93
Current Volume	1607.8k
Average Volume	1434.5k

Piotroski VR‑10 (Strict, 0-10) 1.5

Net Income (-56.8m TTM) > 0 and > 6% of Revenue (6% = 5.50m TTM)

FCFTA -0.24 (>2.0%) and ΔFCFTA -2.81pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue 96.39% (prev 154.6%; Δ -58.24pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA -0.23 (>3.0%) and CFO -32.1m > Net Income -56.8m (YES >=105%, WARN >=100%)

NO Net Debt/EBITDA fails (EBITDA <= 0)

Current Ratio 4.86 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (40.9m) change vs 12m ago 4.23% (target <= -2.0% for YES)

Gross Margin 73.30% (prev 73.91%; Δ -0.61pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 59.97% (prev 47.37%; Δ 12.60pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio -17.27 (EBITDA TTM -54.4m / Interest Expense TTM 3.23m) >= 6 (WARN >= 3)

Altman Z'' -17.17

(A) 0.64 = (Total Current Assets 111.2m - Total Current Liabilities 22.9m) / Total Assets 138.3m

(B) -3.70 = Retained Earnings (Balance) -511.1m / Total Assets 138.3m

warn (B) unusual magnitude: -3.70 — check mapping/units

(D) -6.53 = Book Value of Equity -511.1m / Total Liabilities 78.2m

Total Rating: -17.17 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 33.74

1. Piotroski 1.50pt = -3.50

2. FCF Yield -72.93% = -5.0

3. FCF Margin -35.59% = -7.50

4. Debt/Equity 0.94 = 2.07

5. Debt/Ebitda 0.37 = 2.40

6. ROIC - WACC (= -56.40)% = -12.50

7. RoE -77.58% = -2.50

8. Rev. Trend 92.18% = 6.91

9. EPS Trend 67.05% = 3.35

What is the price of LUNG shares?

As of November 18, 2025, the stock is trading at USD 1.49 with a total of 1,607,766 shares traded.
Over the past week, the price has changed by -23.20%, over one month by -5.10%, over three months by -6.88% and over the past year by -75.65%.

Is Pulmonx a good stock to buy?

No, based on ValueRay´s Fundamental Analyses, Pulmonx (NASDAQ:LUNG) is currently (November 2025) a stock to sell. It has a ValueRay Fundamental Rating of 33.74 and therefor a negative outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of LUNG is around 0.81 USD . This means that LUNG is currently overvalued and has a potential downside of -45.64%.

Is LUNG a buy, sell or hold?

Pulmonx has received a consensus analysts rating of 4.29. Therefore, it is recommended to buy LUNG.

Strong Buy: 4
Buy: 1
Hold: 2
Sell: 0
Strong Sell: 0

What are the forecasts/targets for the LUNG price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	5.8	285.9%
Analysts Target Price	5.8	285.9%
ValueRay Target Price	0.9	-40.9%

LUNG Fundamental Data Overview November 17, 2025

Market Cap USD = 64.7m (64.7m USD * 1.0 USD.USD)
P/E Forward = 28.3286
P/S = 0.706
P/B = 1.0375
Beta = 0.207
Revenue TTM = 91.7m USD
EBIT TTM = -55.7m USD
EBITDA TTM = -54.4m USD
Long Term Debt = 37.0m USD (from longTermDebt, last quarter)
Short Term Debt = 1.24m USD (from shortTermDebt, last quarter)
Debt = 56.6m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -20.0m USD (from netDebt column, last quarter)
Enterprise Value = 44.7m USD (64.7m + Debt 56.6m - CCE 76.5m)
Interest Coverage Ratio = -17.27 (Ebit TTM -55.7m / Interest Expense TTM 3.23m)
FCF Yield = -72.93% (FCF TTM -32.6m / Enterprise Value 44.7m)
FCF Margin = -35.59% (FCF TTM -32.6m / Revenue TTM 91.7m)
Net Margin = -61.91% (Net Income TTM -56.8m / Revenue TTM 91.7m)
Gross Margin = 73.30% ((Revenue TTM 91.7m - Cost of Revenue TTM 24.5m) / Revenue TTM)
Gross Margin QoQ = 74.65% (prev 72.11%)
Tobins Q-Ratio = 0.32 (Enterprise Value 44.7m / Total Assets 138.3m)
Interest Expense / Debt = 1.42% (Interest Expense 805.0k / Debt 56.6m)
Taxrate = -0.93% (negative due to tax credits) (128.0k / -13.8m)
NOPAT = -56.2m (EBIT -55.7m * (1 - -0.93%)) [loss with tax shield] [negative tax rate / tax credits]
Current Ratio = 4.86 (Total Current Assets 111.2m / Total Current Liabilities 22.9m)
Debt / Equity = 0.94 (Debt 56.6m / totalStockholderEquity, last quarter 60.0m)
Debt / EBITDA = 0.37 (negative EBITDA) (Net Debt -20.0m / EBITDA -54.4m)
Debt / FCF = 0.61 (negative FCF - burning cash) (Net Debt -20.0m / FCF TTM -32.6m)
Total Stockholder Equity = 73.1m (last 4 quarters mean from totalStockholderEquity)
RoA = -41.04% (Net Income -56.8m / Total Assets 138.3m)
RoE = -77.58% (Net Income TTM -56.8m / Total Stockholder Equity 73.1m)
RoCE = -50.59% (EBIT -55.7m / Capital Employed (Equity 73.1m + L.T.Debt 37.0m))
RoIC = -50.99% (negative operating profit) (NOPAT -56.2m / Invested Capital 110.3m)
WACC = 5.40% (E(64.7m)/V(121.3m) * Re(8.87%) + D(56.6m)/V(121.3m) * Rd(1.42%) * (1-Tc(-0.01)))
Discount Rate = 8.87% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 3.28%
Fair Price DCF = unknown (Cash Flow -32.6m)
EPS Correlation: 67.05 | EPS CAGR: 14.90% | SUE: 2.18 | # QB: 1
Revenue Correlation: 92.18 | Revenue CAGR: 12.84% | SUE: 1.12 | # QB: 1

Additional Sources for LUNG Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle